ArticlePharmaceuticals (Basel, Switzerland)2020
A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- In vitro and in silico studies and a systematic literature review of antiglycation properties of amlodipine.Scientific reports · 2025Pooled it
- Antiglycoxidative properties of amantadine - a systematic review and comprehensive in vitro study.Journal of enzyme inhibition and medicinal chemistry · 2023Pooled it
- The Effect of Aminoguanidine on Fibrinogen Gene Expression and Oxidative Stress Biomarkers in the Liver Tissue of a Streptozotocin-Induced Diabetic Rat ModelTurkish journal of pharmaceutical sciences · 2026Article
- Meloxicam mitigated methylglyoxal-induced glycative stress in rats.Iranian journal of basic medical sciences · 2025Article
- Article
- Curcumin Co-Encapsulation Potentiates Anti-Arthritic Efficacy of Meloxicam Biodegradable Nanoparticles in Adjuvant-Induced Arthritis Animal Model.Biomedicines · 2023Article
- Unlocking the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2023Article
- Antioxidant and Anti-Glycation Potential of H2 Receptor Antagonists-In Vitro Studies and a Systematic Literature Review.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drugs in Dentistry.Medical science monitor : international medical journal of experimental and clinical research · 2023Review
- Urine 3-Nitrotyrosine and Serum HDL as Potential Biomarkers of Depression.Journal of clinical medicine · 2023Article
- Preliminary evaluation of the antiglycoxidant activity of verapamil using variousFrontiers in pharmacology · 2023Article
- The Assessment of Meloxicam Phototoxicity in Human Normal Skin Cells: In Vitro Studies on Dermal Fibroblasts and Epidermal Melanocytes.Molecules (Basel, Switzerland) · 2022Article
- Salivary gland dysfunction and salivary redox imbalance in patients with Alzheimer's disease.Scientific reports · 2021Article
- Salivary Biomarkers of Oxidative Stress and Inflammation in Stroke Patients: From Basic Research to Clinical Practice.Oxidative medicine and cellular longevity · 2021Review
- Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review andOxidative medicine and cellular longevity · 2021Review
- The Effect of Selected Dental Materials Used in Conservative Dentistry, Endodontics, Surgery, and Orthodontics as Well as during the Periodontal Treatment on the Redox Balance in the Oral Cavity.International journal of molecular sciences · 2020Review
- Bariatric Surgery Normalizes Protein Glycoxidation and Nitrosative Stress in Morbidly Obese Patients.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- Salivary Gland Dysfunction in Stroke Patients Is Associated with Increased Protein Glycoxidation and Nitrosative Stress.Oxidative medicine and cellular longevity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meloxicam is a non-steroidal anti-inflammatory drug, which has a preferential inhibitory effect to cyclooxyganase-2 (COX-2). Although the drug inhibits prostaglandin synthesis, the exact mechanism of meloxicam is still unknown. This is the first study to assess the effect of meloxicam on protein glyco-oxidation as well as antioxidant activity. For this purpose, we used an in vitro model of oxidized bovine serum albumin (BSA). Glucose, fructose, ribose, glyoxal and methylglyoxal were used as glycating agents, while chloramine T was used as an oxidant. We evaluated the antioxidant properties of albumin (2,2-di-phenyl-1-picrylhydrazyl radical scavenging capacity, total antioxidant capacity and ferric reducing antioxidant power), the intensity of protein glycation (Amadori products, advanced glycation end products) and glyco-oxidation (dityrosine, kynurenine, N-formylkynurenine, tryptophan and amyloid-β) as well as the content of protein oxidation products (advanced oxidation protein products, carbonyl groups and thiol groups). We have demonstrated that meloxicam enhances the antioxidant properties of albumin and prevents the protein oxidation and glycation under the influence of various factors such as sugars, aldehydes and oxidants. Importantly, the antioxidant and anti-glycating activity is similar to that of routinely used antioxidants such as captopril, Trolox, reduced glutathione and lipoic acid as well as protein glycation inhibitors (aminoguanidine). Pleiotropic action of meloxicam may increase the effectiveness of anti-inflammatory treatment in diseases with oxidative stress etiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.